Payment overview · 2025
General Payments
$85.91
4 reported records · 4 companies
Healthcare provider profile · identity verified
Eric John Gravois, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PIERRE PART, LA · NPI 1467746628
Verified facts
What the public records show
CMS Open Payments records show Eric John Gravois, M.D. received $85.91 in general payments during 2025 across 4 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.65 | 29.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.79 | 25.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.67 | 24.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.80 | 20.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $60.26 | 3 |
| Education | $25.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 243 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
243 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 596 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 515 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 95 |
| Gabapentin | Gabapentin | 455 | 82 |
| Jardiance | Empagliflozin | 433 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 404 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 366 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 341 | 53 |
| Lisinopril | Lisinopril | 315 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 289 | 54 |
| Alprazolam | Alprazolam | 280 | 55 |
| Montelukast Sodium | Montelukast Sodium | 262 | 57 |
| Furosemide | Furosemide | 249 | 47 |
| Eliquis | Apixaban | 243 | 19 |
| Omeprazole | Omeprazole | 237 | 44 |
| Metformin Hcl | Metformin Hcl | 215 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 212 | 33 |
| Losartan Potassium | Losartan Potassium | 208 | 38 |
| Potassium Chloride | Potassium Chloride | 208 | 31 |
| Trazodone Hcl | Trazodone Hcl | 191 | 35 |
| Sertraline Hcl | Sertraline Hcl | 183 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 51 |
| Donepezil Hcl | Donepezil Hcl | 162 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 33 |
| Prednisone | Prednisone | 152 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 19 |
| Famotidine | Famotidine | 144 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 23 |
| Meloxicam | Meloxicam | 136 | 34 |
| Glimepiride | Glimepiride | 135 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 130 | 33 |
| Olanzapine | Olanzapine | 125 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 125 | 18 |
| Mirtazapine | Mirtazapine | 120 | 19 |
| Finasteride | Finasteride | 116 | 22 |
| Celecoxib | Celecoxib | 111 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 36 |
| Levetiracetam | Levetiracetam | 101 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 23 |
| Clonazepam | Clonazepam | 94 | 17 |
| Allopurinol | Allopurinol | 91 | 18 |
| Metformin Hcl Er | Metformin Hcl | 91 | 21 |
| Trulicity | Dulaglutide | 88 | suppressed |
| Carvedilol | Carvedilol | 87 | 23 |
| Memantine Hcl | Memantine Hcl | 80 | 14 |
| Tramadol Hcl | Tramadol Hcl | 78 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 12 |
| Alendronate Sodium | Alendronate Sodium | 77 | 12 |
| Mounjaro | Tirzepatide | 76 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 69 |
| Ozempic | Semaglutide | 74 | 15 |
| Pregabalin | Pregabalin | 74 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 11 |
| Baclofen | Baclofen | 69 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 69 | 12 |
| Lorazepam | Lorazepam | 68 | 14 |
| Chlorthalidone | Chlorthalidone | 67 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 17 |
| Latanoprost | Latanoprost | 64 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 53 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 14 |
| Cephalexin | Cephalexin | 62 | 42 |
| Propranolol Hcl | Propranolol Hcl | 61 | suppressed |
| Torsemide | Torsemide | 60 | suppressed |
| Ezetimibe | Ezetimibe | 59 | 11 |
| Simvastatin | Simvastatin | 58 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 11 |
| Azithromycin | Azithromycin | 55 | 49 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 11 |
| Temazepam | Temazepam | 52 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | suppressed |
| Sucralfate | Sucralfate | 51 | 15 |
| Levofloxacin | Levofloxacin | 49 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 24 |
| Nifedipine Er | Nifedipine | 48 | 12 |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Cefdinir | Cefdinir | 46 | 44 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 11 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Lactulose | Lactulose | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Scopolamine | Scopolamine | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 28 |
| Linzess | Linaclotide | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 33 |
| Estradiol | Estradiol | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Restasis | Cyclosporine | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 17 |
| Ondansetron Odt | Ondansetron | 28 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Colchicine | Colchicine | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Diazepam | Diazepam | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.91 · 4 records | Takeda Pharmaceuticals U.S.A., Inc. | AREXVY, ELIQUIS, NURTEC ODT, OTEZLA, REPATHA, SHINGRIX, TRINTELLIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error